Nav: Home

Cancer Research UK boosts efforts to overcome deadliest cancer as rates climb

July 19, 2016

CANCER RESEARCH UK has tripled its investment in pancreatic cancer, one of the hardest cancers to treat, since launching its research strategy in 2014 according to new figures published today (Wednesday).

The charity increased spending on pancreatic cancer research -- including improving diagnosis and treatment - to £18million in the 2015/16 financial year, tripling the £6million investment in 2013/14.

One of the charity's aims is to help tackle the rising rates of pancreatic cancer, in particular in women, as well improving poor survival from the disease.

Only one in every 100 pancreatic cancer patients in England and Wales survive their disease for more than 10 years and this has stayed the same since the 1970s.

Worryingly, rates of pancreatic cancer have gone up by nine per cent in the UK over the past decade*.

Over this same period the number of people in the UK dying from pancreatic cancer has increased **.

This means 4,800 women were diagnosed with pancreatic cancer and 4,400 died from the disease in 2014, rising from 3,900 cases and 3,700 deaths in 2004.

Among men, 4,800 were diagnosed with the disease and 4,400 died from it in 2014. This increased from 3,700 cases and 3,400 deaths in 2004.

Figures for England published this week show that pancreatic cancer has the lowest per cent of cases diagnosed at an early stage, with just over one in five (21 per cent) being diagnosed at stage I/II***.

These Cancer Research UK figures are announced to coincide with new TV advertisements for the "Right Now" campaign****. The campaign is designed to highlight the personal impact of cancer in a series of 30 second films and outdoor posters which show the experience of patients going through treatment or being told test results.

Cancer Research UK hopes the campaign will highlight that cancer continues to have an emotional and physical impact, and that research is happening right now to develop better treatments and improve survival for people affected by the disease.

Cancer Research UK also wants to offer hope as it increases funding into pancreatic cancer research across the country, ranging from clinical trials to find the best chemotherapy combinations to give patients after surgery, to discovering the faulty genes and molecules that make pancreatic cancer grow and spread.

In 2014 Cancer Research UK recruited world-leading pancreatic cancer research expert, Professor Andrew Biankin from Australia, to work at the Cancer Research UK Glasgow Centre.

Professor Biankin now leads a team helping to unearth the genetic and molecular secrets hidden within the biggest collection of pancreatic tumour samples in the world. His findings could lead to better ways of matching therapies to patients, and uncover new avenues for treatment.

Professor Biankin said: "Pancreatic cancer is an inherently aggressive disease and it's often diagnosed late, which puts it a step ahead of us when we come to treat it. We need to be more ambitious and hit the disease hard and fast with new approaches. We need to diagnose these cancers swiftly so patients can get onto clinical trials which may help them.

"Throughout my career I've been determined to increase how much we know about pancreatic cancer. Right now, I'm studying differences in pancreatic cancer cells to find new ways to predict the best treatment for each patient. Increasing the amount of research taking place in the UK allows us to be much more optimistic about the future of beating this cancer."

Carl, 42, from Leeds, runs a street food business and was diagnosed with pancreatic cancer in 2012. He was a regular at the gym and ate well, but had started to have pains on the right-hand side of his rib cage.

After visiting his GP with jaundice Carl was referred to hospital where he was diagnosed with pancreatic cancer. He had surgery and chemotherapy to treat the disease. Unfortunately his cancer returned in November 2013, this time affecting his liver and he had another three months of chemotherapy. The cancer has returned twice more since and Carl has needed more treatment each time. Carl is currently in remission and having a break from chemotherapy.

Carl appears in one of the Right Now campaign posters. He is asleep in his hospital bed as his mum looks on.

Carl said: "Before cancer happens to you or a loved one you don't often see inside the hospital, so people have lots of assumptions of what it's like. I wanted to take part in the Right Now campaign to show the reality of my cancer treatment -- it hasn't always been easy. And I think it's also important to talk about how Cancer Research UK is helping develop new treatments for people like me in the future, through clinical trials and research.

"It's encouraging to hear that the charity is investing more in pancreatic cancer so that more patients can take part in clinical trials and scientists can get to the root of the disease. Seeing the charity's work in action and knowing that it's growing gives me great hope for the future."

Sir Harpal Kumar, Cancer Research UK's chief executive, said: "In 2014 we prioritised increased investment in pancreatic, lung, and oesophageal cancers and brain tumours in our research strategy as survival rates in these cancers remain appallingly low, and they are extremely difficult to treat when diagnosed at a late stage.

"To ensure we make a real difference in these cancers we only fund the best research, as determined by international experts, so it's a credit to the excellence of our growing team of scientists that we've been able to increase our activity in these areas this significantly."
-end-
For media enquiries contact Emily Head in the Cancer Research UK press office on 020-3469-6189 or, out of hours, on 07050-264-059.

Notes to editor:

* Between 2003 and 2005 15 people in every 100,000 were diagnosed with the disease, compared with 17 in every 100,000 between 2012 and 2014.

This includes 14 women in every 100,000 between 2003 and 2005, compared with 15 in every 100,000 between 2012 and 2014. And 17 men in every 100,000 between 2003 and 2005, compared with 18 in every 100,000 between 2012 and 2014.

An estimated 37 per cent of pancreatic cancers in the UK are linked to lifestyle factors including smoking, and being overweight or obese.

** The number of people in the UK dying from pancreatic cancer has increased by seven per cent. 14 people in every 100,000 between 2003 and 2005 compared with 15 in every 100,000 between 2012 and 2014.

*** National Cancer Registration and Analysis Service. Stage Breakdown by CCG 2014. London: NCRAS; 2016. http://www.ncin.org.uk/publications/survival_by_stage

**** Clip available here: https://www.youtube.com/watch?v=_WtXDnNoGGA&list=PLr5-SOgrB_UpW9WmYytaI_rrLhTvId6-h&index=9

The latest adverts for the "Right Now" campaign began airing on 27 June 2016 and will run until 24 July 2016. It includes a series of short 30 second films which show the experience of patients going through treatment or being told test results. The campaign recorded patients, their families, friends and the dedicated hospital staff and researchers at Southampton, Leeds and

London's St Bart's.

Cancer Research UK hopes the campaign will highlight that cancer continues to have an emotional and physical impact, and that research is happening right now to develop better treatments and improve survival for those people affected by the disease.

Cancer Research UK

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...